FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950453584> ?p ?o ?g. }

• W2950453584 endingPage "281" @default.
• W2950453584 startingPage "280" @default.
• W2950453584 abstract "Background: Primary myelofibrosis (PMF) together with polycythemia vera (PV) and essential thrombocythemia (ET) belongs to the classic Philadelphia-negative myeloproliferative neoplasms (MPNs). PV and ET can evolve to secondary myelofibrosis (SMF) giving rise to post-PV (PPV) and post-ET (PET) myelofibrosis (MF). PMF and SMF patients are currently managed in the same way and prediction of survival is based on the same prognostic models, even if it has been demonstrated that they can’t accurately distinguish different risk categories in SMF. In the last few years interest grew concerning the ability of gene expression profiling (GEP) to provide valuable prognostic information for clinical decision making. Several studies demonstrated that GEP can improve risk classification in hematologic malignancies such as AML, MDS and lymphoma. Aims: As a preliminary result we performed GEP in PMF and SMF CD34+ cells and identified a gene signature that was able to distinguish patients with a better prognosis from that with a worse one. To confirm these results and to ease the possible clinical use of a molecular signature based on gene expression we decided to move to a more accessible cell population. Methods: Granulocytes were isolated from 114 MF patients (35 prefibrotic/early PMF, 37 overt PMF, 26 PET and 16 PPV) and total cellular RNA was extracted. Gene expression profiling (GEP) was performed using Affymetrix platform. In order to identify genes whose expression is related to survival in MF patients, we performed a Cox regression analysis by means of Partek GS Software. Results: Cox regression analysis led to the identification of a list of 650 transcripts which discriminate high-risk (HR) MF patients from low-risk (LR) ones. According to our results, the frequency of deceased patients was increased in the HR group and survival curves demonstrated that the median overall survival was lower in the HR group compared to the LR one (3.25 y vs 6.88 y, Log-rank p-value <0.01). Moreover, we observed that 11 out of 13 AML transformed patients clustered within the HR group. Interestingly, we found that HR group was enriched in patients carrying at least one high molecular risk mutation (EZH2, ASXL1, IDH1/2, SRSF2), while there was no significant difference between the two groups regarding the disease and the driver mutation. Concerning clinical variables, we observed that median age at diagnosis was higher in the HR group (65.6 y vs 62.1 y, p-value <0.05). WBC count was increased in the HR group (12.9 x109/L vs 9.3 x109/L, p-value <0.05), while platelet count was decreased in the same group compared to LR ones (218 x109/L vs 352 x109/L, p-value <0.01). Moreover, the percentage of patients with more than 1% circulating blasts is greater in the HR group. Finally, we studied the distribution of samples classified according to DIPSS prognostic model. Strikingly, our gene signature classifies as HR several patients belonging to the DIPSS low and intermediate-1 categories. These patients are deceased or leukemia transformed into a shorter time frame than the median survival reported for the reference prognostic class. Summary/Conclusion: Our results demonstrate that GEP of primary MF cells colud be a useful tool for risk prediction in PMF and SMF since it can improve the identification of patients’ subgroups characterized by a poor prognosis. These results should be validated in independent patient cohorts in order to confirm their predictive power." @default.
• W2950453584 created "2019-06-27" @default.
• W2950453584 creator A5000506070 @default.
• W2950453584 creator A5009381933 @default.
• W2950453584 creator A5013539196 @default.
• W2950453584 creator A5015137155 @default.
• W2950453584 creator A5018474393 @default.
• W2950453584 creator A5019208096 @default.
• W2950453584 creator A5019241495 @default.
• W2950453584 creator A5021572378 @default.
• W2950453584 creator A5024737535 @default.
• W2950453584 creator A5025314502 @default.
• W2950453584 creator A5025845066 @default.
• W2950453584 creator A5028827650 @default.
• W2950453584 creator A5034654609 @default.
• W2950453584 creator A5039693085 @default.
• W2950453584 creator A5041959275 @default.
• W2950453584 creator A5046772202 @default.
• W2950453584 creator A5050011235 @default.
• W2950453584 creator A5051772996 @default.
• W2950453584 creator A5054994032 @default.
• W2950453584 creator A5055401685 @default.
• W2950453584 creator A5058522501 @default.
• W2950453584 creator A5064975574 @default.
• W2950453584 creator A5072484806 @default.
• W2950453584 creator A5074623639 @default.
• W2950453584 creator A5077942090 @default.
• W2950453584 creator A5086403807 @default.
• W2950453584 date "2019-06-01" @default.
• W2950453584 modified "2023-09-25" @default.
• W2950453584 title "PF655 PROGNOSTIC RELEVANCE OF THE GENE EXPRESSION SIGNATURE IN PRIMARY AND SECONDARY MYELOFIBROSIS" @default.
• W2950453584 doi "https://doi.org/10.1097/01.hs9.0000560904.67439.75" @default.
• W2950453584 hasPublicationYear "2019" @default.
• W2950453584 type Work @default.
• W2950453584 sameAs 2950453584 @default.
• W2950453584 citedByCount "0" @default.
• W2950453584 crossrefType "journal-article" @default.
• W2950453584 hasAuthorship W2950453584A5000506070 @default.
• W2950453584 hasAuthorship W2950453584A5009381933 @default.
• W2950453584 hasAuthorship W2950453584A5013539196 @default.
• W2950453584 hasAuthorship W2950453584A5015137155 @default.
• W2950453584 hasAuthorship W2950453584A5018474393 @default.
• W2950453584 hasAuthorship W2950453584A5019208096 @default.
• W2950453584 hasAuthorship W2950453584A5019241495 @default.
• W2950453584 hasAuthorship W2950453584A5021572378 @default.
• W2950453584 hasAuthorship W2950453584A5024737535 @default.
• W2950453584 hasAuthorship W2950453584A5025314502 @default.
• W2950453584 hasAuthorship W2950453584A5025845066 @default.
• W2950453584 hasAuthorship W2950453584A5028827650 @default.
• W2950453584 hasAuthorship W2950453584A5034654609 @default.
• W2950453584 hasAuthorship W2950453584A5039693085 @default.
• W2950453584 hasAuthorship W2950453584A5041959275 @default.
• W2950453584 hasAuthorship W2950453584A5046772202 @default.
• W2950453584 hasAuthorship W2950453584A5050011235 @default.
• W2950453584 hasAuthorship W2950453584A5051772996 @default.
• W2950453584 hasAuthorship W2950453584A5054994032 @default.
• W2950453584 hasAuthorship W2950453584A5055401685 @default.
• W2950453584 hasAuthorship W2950453584A5058522501 @default.
• W2950453584 hasAuthorship W2950453584A5064975574 @default.
• W2950453584 hasAuthorship W2950453584A5072484806 @default.
• W2950453584 hasAuthorship W2950453584A5074623639 @default.
• W2950453584 hasAuthorship W2950453584A5077942090 @default.
• W2950453584 hasAuthorship W2950453584A5086403807 @default.
• W2950453584 hasBestOaLocation W29504535841 @default.
• W2950453584 hasConcept C104317684 @default.
• W2950453584 hasConcept C126322002 @default.
• W2950453584 hasConcept C143998085 @default.
• W2950453584 hasConcept C150194340 @default.
• W2950453584 hasConcept C18431079 @default.
• W2950453584 hasConcept C2778837598 @default.
• W2950453584 hasConcept C2779733811 @default.
• W2950453584 hasConcept C2780007613 @default.
• W2950453584 hasConcept C2780076729 @default.
• W2950453584 hasConcept C2781057849 @default.
• W2950453584 hasConcept C2908647359 @default.
• W2950453584 hasConcept C502942594 @default.
• W2950453584 hasConcept C50382708 @default.
• W2950453584 hasConcept C54355233 @default.
• W2950453584 hasConcept C63363279 @default.
• W2950453584 hasConcept C71924100 @default.
• W2950453584 hasConcept C86803240 @default.
• W2950453584 hasConcept C99454951 @default.
• W2950453584 hasConceptScore W2950453584C104317684 @default.
• W2950453584 hasConceptScore W2950453584C126322002 @default.
• W2950453584 hasConceptScore W2950453584C143998085 @default.
• W2950453584 hasConceptScore W2950453584C150194340 @default.
• W2950453584 hasConceptScore W2950453584C18431079 @default.
• W2950453584 hasConceptScore W2950453584C2778837598 @default.
• W2950453584 hasConceptScore W2950453584C2779733811 @default.
• W2950453584 hasConceptScore W2950453584C2780007613 @default.
• W2950453584 hasConceptScore W2950453584C2780076729 @default.
• W2950453584 hasConceptScore W2950453584C2781057849 @default.
• W2950453584 hasConceptScore W2950453584C2908647359 @default.
• W2950453584 hasConceptScore W2950453584C502942594 @default.
• W2950453584 hasConceptScore W2950453584C50382708 @default.
• W2950453584 hasConceptScore W2950453584C54355233 @default.
• W2950453584 hasConceptScore W2950453584C63363279 @default.
• W2950453584 hasConceptScore W2950453584C71924100 @default.

• next